Rationale-Rnd3, a small Rho GTPase, is involved in the regulation of cell actin cytoskeleton dynamics, cell migration, and proliferation. The biological function of Rnd3 in the heart remains unexplored.
INTRODUCTION
Rnd3, also known as RhoE, is one of the Rnd subsets of the Rho-family GTPases. It is generally believed that it functions as a repressor of Rho-associated coiled-coil protein kinase 1 (ROCK1). [1] [2] [3] [4] In contrast to the canonical mode of Rho-family proteins, members of the Rnd subfamily, including Rnd1, Rnd2, and Rnd3, bind but do not hydrolyze GTP. They are defective in GTPase activity, even in the presence of RhoGAPs. [5] [6] [7] [8] The study of the regulatory activation of ROCK1 demonstrated that Rnd3 inhibits RhoA-mediated ROCK1 signaling by specifically binding to ROCK1, but not ROCK2. 1, 2 Rnd3 is the only endogenous ROCK1 antagonist discovered so far. 4 The current knowledge about the biological functions of Rnd3 has been mainly achieved by in vitro cell culture studies and tissue screening assays including gain-and loss-of-function approaches. Overexpression of Rnd3 inhibited ROCK1-mediated biological effects including stress fiber formation, phosphorylation of myosin light chain phosphatase, and apoptosis. Reduced expression of Rnd3 potentiated ROCK1 activity. 1, 2, 9 . Rnd3 is also a substrate of ROCK1. The ROCK1-Rnd3 interaction mediates Rnd3 phosphorylation by ROCK1 at multiple sites within its Nand C-terminals, which stabilizes the Rnd3 protein, regulates Rnd3 cellular localization, and forms a negative feedback loop to ROCK1. 10, 11 Emerging evidence suggests that Rnd3 might be involved in the regulation of the cell cycle, 12 as well as cancer cell migration and invasion. 13, 14 We recently uncovered a Rho kinase-independent function of Rnd3, and reported that genetic deletion of Rnd3 led to aqueductal stenosis in mouse brains through upregulation of Notch signaling. 15 Two studies found that Rnd3 was indispensable in mouse neuron development, 16, 17 suggesting Rnd3 is involved in much broader biological functions besides its inhibitory effect on Rho kinase. In this study, we provide evidence to reveal a function of Rnd3, in which Rnd3 regulates the β 2 AR-PKA signaling pathway. Deficiency of Rnd3 leads to global activation of PKA in vitro in cardiac and non-cardiac cells, and in vivo in animal hearts. The latter develops fetal arrhythmias through the destabilization of RyR2 calcium release channels.
Fetal or neonatal heart arrhythmias in humans are a common disorder. While the type and severity of congenital arrhythmias vary, some are life-threatening. 18 Only limited genetic mutations leading to fetal arrhythmias have been identified. 19 Continued identification of new genes/loci linked to fetal arrhythmias will expand our knowledge of the genetic components of the disease, and will have significant impacts on the disease diagnosis, prognosis, and treatment. Here, we present an animal model with fetal arrhythmias and reveal that the activation of the β 2 -adrenergic receptor-protein kinase A (β 2 ARPKA) signaling pathway contributes to the Rnd3 deficiency-mediated arrhythmic phenotype. In the mechanistic study, we provide evidence that the downregulation of Rnd3 is sufficient to initiate the activation of PKA signaling in vivo in animal hearts and in vitro in both cardiac and non-cardiac cells, suggesting a general mechanism for Rnd3-mediated PKA regulation. We further determine that Rnd3 is a regulator in the β 2 AR ubiquitination regulatory complex. Rnd3 regulates β 2 AR ubiquitination, mediated by the physical interaction between both proteins. The lack of Rnd3 prevents the ubiquitination of β 2 AR, resulting in the accumulation of β 2 AR protein. Excess β 2 AR promotes the activation of PKA signaling, which then contributes to the dysfunction of RyR2 calcium release channels. The β 2 AR antagonist treatment significantly reduced arrhythmia and improved cardiac contractility.
The pathological consequence of Rnd3 downregulation in the heart is unknown. By searching databases, we found one microarray screening study that showed a significant decrease in the Rnd3 mRNA levels in failing human myocardium (Profile GDS651/212724_at/RND3 in NCBI GEO profiles). The etiologic meaning of Rnd3 downregulation in human heart failure and arrhythmogenesis remains obscure. Clearly, our Rnd3-null mouse study provides a mechanistic base for the future investigation in humans.
METHODS
Methods and any associated references are provided in detail in the online version of the paper.
RESULTS

Genetic deletion of the Rnd3 gene in mice results in embryonic lethality with fetal heart arrhythmias
Rnd3 knockout mice were generated from a gene trap ES cell line. The targeting vector was inserted at Rnd3 intron 2 (Fig. 1A) . The deletion of the Rnd3 gene was verified by PCR genotyping (Fig. 1B) and Southern blotting (Fig. 1C ). q-PCR ( Fig. 1D ) and Western blot ( Fig. 1E ) assessments of the Rnd3 transcript and protein levels confirmed the Rnd3 knockout. No obvious morphological changes were observed in the mutant embryonic hearts (Online Fig. I ). Genotyping results revealed that the majority of Rnd3-null mice died between E10.5 and E12.5 (Online Table I ). To evaluate embryonic mouse cardiac functions in vivo, we performed echocardiographic analyses in female mouse wombs. Rnd3-null mice showed severe decreases in the cardiac ejection fraction and fractional shortening compared to wild-type control mice (Online Table II ). Due to the technological challenges, we were not able to measure an individual mouse embryo electrocardiography (ECG), therefore, we assessed heart beats using echocardiography, and detected cardiac arrhythmias in E11 Rnd3null mice (Online Video I and Video II).
Rnd3 −/− cardiomyocytes display an abnormal intracellular Ca 2+ release
To explore a possible mechanism contributing to the arrhythmogenicity, we analyzed cardiomyocytes isolated from E10.5 embryonic hearts. We found that Rnd3 −/− cardiomyocytes exhibited a significant increase in spontaneous rhythm ( Fig. 2A ) as shown by the increased frequency of Ca 2+ oscillations (1.62 ± 0.16/Hz) compared to the WT (1.04 ± 0.12/Hz) ( Fig. 2B ). The amplitude of the spontaneous Ca 2+ transient, however, was reduced by 27% in Rnd3 −/− cardiomyocytes (1.72 ± 0.09 F1/F0) compared to WT myocytes (2.35 ± 0.12 F1/F0) ( Fig. 2C upper and lower panels). Further experiments revealed obvious Ca 2+ leakage occurring in Rnd3 −/− cardiomyocytes under sodium-and calcium-free perfusate conditions (without the influences of Ca 2+ pump and Na + /Ca 2+ exchanger (NCX), (Fig. 2D ). The cardiomyocyte sarcoplasmic reticulum (SR) Ca 2+ load showed no significant differences between the two groups ( Fig. 2E ), suggesting normal or compensated sarco/ endoplasmic reticulum Ca 2+ -ATPase (SERCA) and NCX functions. Measurements of the fluorescence decay times (Tau) for Ca 2+ transient decline and Ca 2+ decline in caffeine showed no statistically significant differences between the WT and the Rnd3 mutant hearts, indicating no impairment of the SERCA and NCX functions in the mutant heart ( Fig. 2F and 2G). However, we observed a higher Tau value in SERCA function analysis ( Fig. 2F ), which could be due to the downregulation of the SERCA expression levels and/or a lower SERCA activity. To rule out these possibilities, NCX1 and SERCA2α protein levels, and phospholamban (PLN) phosphorylation at serine 16 in the animal hearts were assessed by immunoblot analyses. No changes in the NCX1 and SERCA2α protein levels were observed in the Rnd3-null heart compared to the WT heart ( Fig. 2H ). Hyperphosphorylation of PLN at serine 16 was detected in the Rnd3 mutant heart (Fig. 2I ). This indicates that the mutant hearts compensate for the Ca 2+ leakage by enhancing SERCA function, although this counter effect may not be sufficient to overcome the overall Ca 2+ leakage shown by a prolonged Tau of Ca 2+ transient decline ( Fig. 2F ). Together, the genetic deletion of Rnd3 resulted in an obvious Ca 2+ leakage phenotype in mouse cardiomyocytes. This leak did not lead to a lower SR Ca 2+ load due to the compensations by SERCA and NCX functions, therefore suggesting a RyR2 Ca 2+ release channel dysfunction.
RyR2 Ca 2+ release channels are destabilized in Rnd3 −/− cardiomyocytes
We then assessed RyR2 single channel function in planar lipid bilayers. 20 While the average RyR2 basal opening probability was not statistically different between Rnd3 −/− mice (0.41 ± 0.06) and WT mice (0.49 ± 0.07) ( Fig. 3A and 3B ), the frequency of the RyR2 opening was three times higher in Rnd3 −/− mouse hearts (44.6 ± 5.5 s −1 ) compared to WT hearts (14.0 ± 3.1 s −1 ) ( Fig. 3D and 3E, respectively). These data suggest that RyR2 channels are destabilized in Rnd3-null cardiomyocytes, contributing to abnormal intracellular Ca 2+ release and an arrhythmogenic phenotype.
Rnd3 knockdown leads to elevated PKA activity and hyperphosphorylation of RyR2
Next, we explored the molecular mechanism of Rnd3 deficiency-mediated RyR2 destabilization. RyR2 Ca 2+ release channels, tetramer proteins, are critical for calcium handling and are tightly regulated. We, as well as others, have demonstrated that RyR2 channel hyperphosphorylation by PKA is closely associated with Ca 2+ dysregulation including SR Ca 2+ leakage, which contributes to cardiac arrhythmias and heart failure. [21] [22] [23] [24] We therefore assessed the protein levels of the active PKA isoform (PKAc) and the phosphorylation status of cyclic AMP-responsive element-binding protein (CREB), a known PKA substrate. The immunoblot data displayed remarkable increases in the PKAc protein levels and the hyperphosphorylation of CREB in the Rnd3 mutant heart (Fig. 4A ). The elevated PKA activation in the Rnd3 mutant heart was also confirmed by the observation of an increase in PLN phosphorylation at serine 16, a major target of PKA in the early immunoblot of this study (Fig. 2I ). In parallel with the assessment of PKA activity, the cAMP levels were measured in mouse embryos. More than a 2-fold increase in the cAMP concentration was detected in Rnd3 −/− E10.5 embryos compared to WT embryos ( Fig. 4B ). Meanwhile, obvious increases in RyR2 phosphorylation levels at serines 2808 and 2030 were observed in Rnd3-null hearts with no changes in the RyR2 total protein expression levels ( Fig. 4C ). Thus, several lines of evidence in vivo indicate that Rnd3 deficiency results in activation of PKA signaling, which leads to RyR2 channel hyperphosphorylation.
To demonstrate that the Rnd3-mediated change in the PKA activity was not due to any secondary or compensated effects by the animal in vivo, we knocked down Rnd3 in neonatal rat cardiomyocytes in vitro using the specific siRNA for Rnd3. Increases in the levels of PKAc protein, CREB hyperphosphorylation, and intracellular cAMP concentrations paralleled the knockdown of Rnd3 expression in the same cohort of rat cardiomyocytes ( Fig.  4D and 4E ). Noticeable increases in RyR2 phosphorylation at serines 2808 and 2030 were detected in siRNA-treated rat cardiomyocytes as well ( Fig. 4F ). These data are consistent with the in vivo results from the Rnd3 mutant mice.
Since PKA signaling is essential for a broad array of biological activities, we examined the Rnd3 deficiency-mediated PKA activation in non-cardiac cells as well. In accordance with our cardiomyocyte results, significant increases in the PKA activity and CREB hyperphosphorylation were observed in mouse embryonic fibroblasts (MEF) isolated from Rnd3 −/− mice (Online Fig. IID ), suggesting a general mechanism of PKA activation regulated by Rnd3. We demonstrated the increased cAMP levels along with the elevated PKA activities both in vivo in the Rnd3-null mouse hearts and embryos, and in vitro in the Rnd3 knockdown cardiac and non-cardiac cells. These data suggest that the downregulation of Rnd3 is sufficient to initiate PKA signaling activation that leads to RyR2 channel hyperphosphorylation.
PKA activation is involved in the Rnd3 deficiency-mediated Ca 2+ leakage
We have demonstrated the activation of PKA induced by Rnd3 downregulation. Now we would like to know if Rnd3 deficiency-mediated Ca 2+ leakage can be blocked by the inhibition of PKA activity. We treated cardiomyocytes with a PKA inhibitor, H89. Consistent with the previous data in this study, we observed four times higher spontaneous Ca 2+ leakage events (SCR) in Rnd3 −/− cardiomyocytes compared to WT cells ( Fig. 5A ). However, the Ca 2+ leakage was blocked by the H89 treatment (Fig. 5A ). The percentage of the mutant cardiomyocyte cells with SCR was double that of the WT cardiomyocytes ( Fig.  5B ). After H89 treatment, this high percentage returned to the level of the WT cardiomyocytes ( Fig. 5B ). This result suggests that PKA activation is involved in the Rnd3 deficiency-mediated Ca 2+ leakage.
In the assessment of PKA activation, we also evaluated RyR2 phosphorylation at serine 2814, a CaMK phosphorylation site. The enhancement of the phosphorylation was detected in the Rnd3 −/− heart (Online Fig. IIIA) . Treatment of the mutant cardiomyocytes with CaMK inhibitor KN93 partially attenuated the Ca 2+ leakage (Online Fig. IIIB ). However, the inhibitory effect on the Ca 2+ leakage by KN93 was moderate compared to the blockage by H89 treatment (Fig. 5 ). Therefore, we focused on PKA activation in this study.
Adult cardiomyocytes with Rnd3 haploinsufficiency (Rnd3 +/− ) also exhibit an abnormal intracellular Ca 2+ release and the Ca 2+ leakage is attenuated by PKA inhibitor treatment
To investigate if the calcium leakage occurred in the adult cardiomyocytes as well, we conducted the same cohort of experiments in the cardiomyocytes isolated from adult Rnd3 +/− mouse hearts. The spontaneous calcium transient incidence in Rnd3 +/− cells was five times higher than that in the wild-type cells (Online 
Adult Rnd3 haploinsufficient mice displayed ventricular arrhythmias
Since Rnd3-null mice are embryonically lethal, we evaluated the electrophysiology of adult Rnd3 heterozygous mice. Nine mice (5 Rnd3 +/− and 4 WT) underwent the electrophysiology study protocol. All mice exhibited sinus rhythm before pacing studies started (Online Fig.  VA ). Baseline programmed electrical stimulation evoked ventricular arrhythmias in 40% (2/5) of Rnd3 +/− mice and none (0/4) in the WT mice (using either ventricular extrastimulus or burst pacing) (Online Fig. VB and VE) . After intraperitoneal injection of isoproterenol (3 mg/kg) and caffeine (120 mg/kg), the average heart rate increased by 16% in both groups (16 ± 6% in WT mice and 16 ± 9% in Rnd3 +/− mice; P=0.73) (Online Fig. VC) . Ventricular arrhythmias were induced in 80% (4/5) of the Rnd3 +/− mice versus 0% (0/4) of the WT mice (P=0.048) by ventricular burst pacing after isoproterenol/caffeine injection (Online Fig. VD and VE). The remaining Rnd3 +/− mouse died following ventricular burst pacing at 40 msec. The ECG rhythm of this mouse revealed sinus bradycardia followed by AV block and asystole. Thus, haploinsufficiency for Rnd3 creates a substrate for ventricular arrhythmias that can be induced by cardiac pacing in particular after beta-adrenergic stimulation.
Rnd3 deficiency results in the elevation of β 2 AR protein levels through the ubiquitination mechanism Finally, we explored the molecular mechanism of the Rnd3 deficiency-mediated PKA activation and found an increase in the β 2 AR, but not β 1 AR, protein levels in the Rnd3-null mouse heart ( Fig. 6A ). Since the assessment of β 2 AR protein expression levels is critical, we validated the specificity of the β 2 AR antibody by probing for β 2 AR expression in the β 1 AR/ β 2 AR double-knockout and the β 2 AR single knockout mouse hearts, respectively (Online Fig. VI) . To further verify and quantify the β 2 AR protein increase detected by the immunoblot analysis, the 125 I-iodocyanopindolol binding assay, a more stringent radioligand method, was used. We observed that the membrane-associated β 2 AR was 10 times higher in Rnd3 −/− hearts (227.4 fmol/mg) compared to the wild-type control hearts (21.36 fmol/mg) ( Fig. 6B ). Interestingly, we did not detect a correlated increase at the β 2 AR mRNA levels in the same cohort of the mutant hearts ( Fig. 6C ). To rule out any possible secondary or compensated effects leading to this increase in β 2 AR protein levels by the animal in vivo, we conducted the same set of experiments in vitro in the neonatal rat cardiomyocytes treated with the siRNA specific for Rnd3. Again, upregulated β 2 AR protein levels were detected by both immunoblot analyses ( Fig. 6D ) and 125 I-iodocyanopindolol binding assay (Fig. 6E ), but the β 1 AR protein levels remained the same. The disconnection of the increase in β 2 AR protein levels without an increase in its transcript levels was also observed (Fig. 6F ). Finally, we forced expression of Rnd3 and found a downregulation of β 2 AR protein levels (Online Fig. VII) .
In the previous experiments, we demonstrated that Rnd3 deficiency-mediated PKA activation was a general mechanism that happened in both cardiac and non-cardiac cells. Therefore, we wanted to know if the β 2 AR protein upregulation occurs without a change in its transcript levels in non-cardiac cells with Rnd3 downregulation. The associated assessments of the β 2 AR protein and mRNA levels in the non-cardiac MEF cells isolated from Rnd3 −/− mice (Online Fig. VIIIA and VIIIB, respectively) , and the HEK293T cells (Online Fig. VIIIC and VIIID, respectively) , and myoblast C2C12 cells (Online Fig. VIIIE and VIIIF, respectively) with Rnd3 knocked down by siRNA were performed. Again, noticeable increase in the β 2 AR protein but not mRNA levels were found. These data strongly suggest that β 2 AR is under post-translational regulation through Rnd3.
Since ubiquitination is a critical post-translational regulatory mechanism for β 2 AR, we investigated whether Rnd3 plays a role in β 2 AR ubiquitination. First, we determined the interaction of Rnd3 and β 2 AR ex vivo by co-transfection of Rnd3 and β 2 AR in HEK293T cells followed by mutual coimmunoprecipitations as shown in Fig. 7A and 7B . Then, the levels of β 2 AR ubiquitination were assessed by immunoprecipitation of β 2 AR followed by anti-ubiquitin immunoblotting analysis under both baseline and isoproterenol (ISO) treatment conditions. As shown in Fig. 7C (in the untreated group) , the amount of ubiquinated species of β 2 AR was significantly reduced by the knockdown of Rnd3 with about a 22% decline in the normalized amount of ubiquitinated β 2 AR compared to the control without ISO treatment (Fig. 7D in the untreated group). Consistent with the baseline result, a 41% reduction in the normalized amount of ubiquitinated β 2 AR in the Rnd3 knockdown group was observed relative to the control (Fig. 7C in ISO group and 7D in ISO group) while the total amount of β 2 AR ubiquitination was increased by the ISO treatment as expected. In parallel with the reductions in β 2 AR ubiquitination, higher expression levels of β 2 AR protein were once again detected in the Rnd3 knockdown groups under both baseline (untreated) and ISO treated conditions by cycloheximide chase analysis ( Fig. 7E and 7F ). β 2 AR lysosomal targeting has been shown as an important mechanism for ubiquinated β 2 AR degradation 25 . We conducted isoproterenol-stimulated β 2 AR lysosomal trafficking experiments to monitor β 2 AR receptor dynamic subcellular localization in a flag-β 2 AR stable expression cell line (293T flag-β2AR cells). Immunostaining for LAMP2 (lysosomeassociated membrane protein 2), a lysosome marker, and β 2 AR was performed followed by fluorescent microscopy analysis. The receptor internalization into lysosomes and endocytic vesicles was visualized ( Fig. 8A) and quantified by the colocalization of β 2 AR with LAMP2 ( Fig. 8B ). In the control group without isoproterenol stimulation, β 2 AR was evenly distributed across the cell membrane with a basal level of β 2 AR within lysosomes. However, Rnd3 deficiency significantly reduced β 2 AR receptor internalization into lysosomes (10.7%) compared to the control group (21.3%), and this attenuated lysosomal trafficking of β 2 AR was still detected 10, 20, and 60 minutes after isoproterenol stimulation. The data indicate that Rnd3 is a critical factor for the integrity of lysosome-mediated β 2 AR regulation. The result is consistent with the regulatory role of Rnd3 in β 2 AR degradation observed early in this study.
Regulation of post-translational modification-mediated βAR degradation is complicated and involves multiple biological processes and factors. Although it is not the focus of the study, we still examined the expression levels of β-arrestin, an adaptor protein of E3 ligase for β 2 AR ubiquitination, and G-protein coupled receptor kinase 2 (Grk2) in the mutant heart since both factors are involved in β 2 AR ubiquitination. No significant differences of the two protein expression levels were detected between the Rnd3-null heart and the wild-type heart (Online Fig. IX) .
We then assessed hydroxylation regulation of β 2 AR receptor and sumoylation modification of arrestin 3 and caveolin-3 in Rnd3 deficient mouse hearts, since hydroxylation and sumoylation are involved in β 2 AR receptor post-translational modification degradation. [26] [27] [28] The former is through Egl-9 family hypoxia-inducible factor 3 (EGLN3), a member of the EGLN family of prolyl hydroxylases, also called prolyl hydroxylase domain-containing protein 3 (PHD3), which catalyzes hydroxylation of β 2 AR and facilitates the receptor ubiquitination by von Hippel-Lindau E3 ubiquitin ligase complex (pVHL). 26 In the sumoylation modification mechanism, arrestin 3 and caveolin-3 sumoylation enhanced β 2 AR internalization and endocytosis. 27, 28 We evaluated the amount of EGLN3 and pVHL binding to β 2 AR by immunoprecipitation followed by immunoblot specific for EGLN3 and pVHL in mouse hearts. As displayed in Online Fig. XA , we did not find significant differences in EGLN3 and pVHL proteins bound to β 2 AR among wild-type, Rnd3 +/− , and Rnd3 −/− animal hearts. Meanwhile, the immunoprecipitation from the same cohort of mouse hearts showed no obvious changes of arrestin 3 and caveolin-3 sumoylation modifications (Online Fig. XB) , indicating a minimal role of hydroxylation and sumoylation in Rnd3mediated β 2 AR regulation.
Finally, we conducted a mouse rescue experiment using ICI118,551, a β 2 AR antagonist. The drug significantly improved Rnd3 −/− embryo mouse cardiac contractility (Online Table II ) and reduced arrhythmia. We only detected arrhythmia in 1 out of 16 mutant embryos.
Together with the previous results, we provide the evidence that Rnd3 is a factor involved in β 2 AR ubiquitination and RyR2 stabilization regulation. Rnd3 deficiency attenuates β 2 AR lysosomal trafficking and ubiquitination, resulting in the prolonged activation of PKA signaling. The latter targets RyR2 channels and leads to channel dysfunction, which eventually contributes to arrhythmias and heart failure in Rnd3-null embryonic hearts. The β 2 AR antagonist treatment reduced arrhythmia and improved cardiac function.
DISCUSSION
The destabilization of RyR2 calcium release channels is responsible for many heart diseases, including cardiac arrhythmias and heart failure. Phosphorylation of RyR2 has been demonstrated as an important modification for its functional integrity. In patients with RyR2 channel mutations, the RyR2 channels exhibit "leaky" defects under PKA phosphorylation conditions, a situation that mimics sympathetic activation during exercise. 29, 30 The PKAmediated destabilization of the RyR2 channels was demonstrated in several mouse models as well. [21] [22] [23] [31] [32] [33] Overexpression of PKA catalytic domain in mouse heart tissues was sufficient to lead to dilated cardiomyopathy and sudden cardiac death. 22 Genetic inhibition of PKA-mediated RyR2 phosphorylation attenuated RyR2 leakage, 23 and prevented heart failure induced by chronic stimulation of β-adrenergic signaling. 34 We would like to indicate that whether PKA-mediated RyR2 phosphorylation at serine 2808 (S2808) directly leads to RyR2 dysfunction remains controversial. 35 Several studies found that genetic alteration of RyR2 channels at S2808, a situation that was suggested to mimic the PKA hyperphosphorylation, showed no different phenotypes in the genetically altered mice compared to the control wild-type mice after stress. [36] [37] [38] This disparity suggests that the PKA-mediated regulation of RyR2 function might be comprehensive and involve multiple factors, various hyperphosphorylation sites, and different biochemical modifications of RyR2 channels. 39, 40 One of the strategies for future study would be to crossbreed the Rnd3null mice with RyR2-S2808A mice, a phosphorylation-resistant mouse strain, to see if the mouse phenotype can be rescued.
The biological function of RyR2 in E-C coupling in fetal hearts has been investigated in many studies. It is not doubted that there is a functional maturation progression in RyR2mediated SR calcium release in embryonic cardiomyocytes during development. Early studies suggested a minimal role of RyR2 in E-C coupling in embryonic cardiomyocytes. 41, 42 However, these results have been challenged by recent studies. [43] [44] [45] More recent studies demonstrated that the major source of calcium transients is from SR through RyR2 in fetal hearts. While the definitive role of RyR2 in embryonic cardiomyocytes still may be far from the conclusion, it is gradually believed that RyR2mediated SR calcium release already functions early in the embryonic heart, which is important for normal fetal heart function and development. [43] [44] [45] Consistent with these studies, we demonstrated the regulatory role of Rnd3 in an embryonic heart, and we also showed that Rnd3 haploinsufficiency is sufficient to induce the calcium leakage in adult cardiomyocytes, indicating a limited effect of cardiac development on Rnd3-mediated calcium regulation. Furthermore, we demonstrated that the adult Rnd3 haploinsufficient mice were hypersensitive to arrhythmogenic stimuli and displayed severe ventricular arrhythmias after cardiac pacing, particularly with beta-adrenergic stimulation. We also recently found that Rnd3 haploinsufficient mice were predisposed to hemodynamic stress and developed heart failure after pressure overload. 46 Agonist binding to G protein-coupled receptors leads to cAMP-dependent PKA activation. Broad arrays of biological and pathological effects are regulated through the activation of this signaling pathway. In this study, we detected a significant increase in PKA activity in both cardiac and non-cardiac cells with Rnd3 downregulation, suggesting a general mechanism of Rnd3-mediated PKA regulation. We further revealed that the elimination of Rnd3 expression resulted in the increase of β 2 AR protein, but there was no increase in the mRNA levels. β 2 AR lysosomal targeting and ubiquitination attenuation contributed to this elevation of β 2 AR protein levels. The molecular mechanism of β 2 AR receptor degradation through ubiquitination and the associated ubiquitin protein ligase (E3) adapter β-arrestin1/2 was first elucidated by Robert J. Lefkowitz. 47 The process is regulated by Grk2 phosphorylation that facilitates β-arrestin binding to the receptor resulting in degradation and/or internalization (desensitization) of the receptor. [48] [49] [50] Clinically, the elevated Grk2 protein levels are detected in lymphocytes from patients that had a myocardial infarction, and are suggested to be inversely associated with patient cardiac functions. 51 To investigate if Grk2 and β-arrestin were involved in Rnd3-mediated β 2 AR receptor degradation, we assessed the expression levels of the two proteins and did not detect the changes of Grk2 and arrestin expression levels in the Rnd3-null heart. Emerging evidence shows that the process of β 2 AR receptor trafficking and degradation are dynamic and complex. Additional new factors have been continually identified in the signalosome complex. 25, [52] [53] [54] We report that Rnd3 is another regulator in the β 2 AR ubiquitination regulatory complex. The lack of Rnd3 prevents the ubiquitination of β 2 AR, despite the normal expression levels of β-arrestin1/2 and Grk2, resulting in the accumulation of β 2 AR protein, which promotes the activation of PKA signaling. Finally, we demonstrated that application of β 2 AR blocker can rescue the mouse phenotype by reserving cardiac contractility and reducing cardiac arrhythmia.
It is important to realize that there is a limitation in this study. It is unclear whether Rnd3 is a constitutively associated factor in the multimeric complex or just a "hit and run" regulatory protein during β 2 AR receptor trafficking and degradation. Further sets of experiments are absolutely necessary. The answer will provide a further mechanism for our understanding of β 2 AR dynamic regulation and calcium release regulation.
Rnd3 has also been shown to play an essential role in the Notch signaling pathway by facilitating NICD protein degradation through ubiquitin proteasome system (UPS) in mouse brains in our recent study. 15 Given the fact that there are more than 600 putative E3 ligases in humans, 55 our future study will investigate whether Rnd3 directly binds to an E3 ligase functioning as an ancillary protein, or interacts with arrestin family members.
In summary, there are five findings in this study. First, the Rnd3 gene is indispensable for mouse development. Rnd3-null mice are embryonically lethal with cardiac arrhythmias. Second, our data reveal that Rnd3 is essential for the normal function of RyR2 Ca 2+ release channels in both the embryonic and adult mouse heart. Genetic deletion of Rnd3 results in Ca 2+ leakage through RyR2 channel destabilization that in turn prompts arrhythmias. Third, we validate that hyperphosphorylation of RyR2 by PKA contributes to Rnd3 deficiencymediated RyR2 dysfunction in mouse hearts. Fourth, we demonstrate that the downregulation of Rnd3 is sufficient to initiate activation of PKA signaling in vivo in animal hearts and in vitro in both cardiac-and non-cardiac cells, suggesting a general mechanism of Rnd3-mediated PKA activation. Finally, we discover the molecular mechanism of Rnd3-mediated PKA activation and determine that Rnd3 is a regulator in the β 2 AR ubiquitination regulatory complex. The lack of Rnd3 prevents the ubiquitination of β 2 AR, resulting in the accumulation of β 2 AR protein, which promotes the activation of PKA signaling (Online Fig. XI) . Given the fundamental roles of the RyR2 channels in cell signaling, arrhythmogenicity, heart failure, and the βAR-PKA signaling pathway, the present findings have both basic and clinical significances and provide a potential new target for pharmacological manipulations.
Nonstandard Abbreviations and Acronyms
Rnd3
Rho family GTPase 3 
Novelty and Significance
What Is Known?
• Small G protein Rnd3 functions as Rho kinase inhibitor involved in cell migration, proliferation, and cytoskeleton dynamics.
• It plays an essential role in central nerve system development.
• It regulates cell cycling, cancer cell migration and invasion.
What New Information Does This Article Contribute?
• Rnd3 participates in intracellular Ca 2+ homeostasis regulation in the mouse heart.
• Rnd3 deficiency results in Ca 2+ leakage through RyR2 channel destabilization that in turn prompts cardiac arrhythmias and heart failure in mice.
• The associated molecular mechanism is that lack of Rnd3 prevents the ubiquitination of β 2 AR, resulting in the accumulation of β 2 AR protein, which promotes the activation of PKA signaling. Increased PKA signaling in turn promotes RyR2 hyperphosphorylation, which contributes to arrhythmogenesis. Application of β 2 AR blocker reduces animal arrhythmia and improves heart function.
Understanding the molecular mechanisms of dynamic regulations of β 2 AR and RyR2 channels is critical for the treatment of cardiac arrhythmias and heart failure. The current findings add new information about Rnd3 as a novel regulator in the β 2 AR ubiquitination, RyR2 channel stability and mouse embryonic development, and provide a potential new target for pharmacological manipulations in cardiac arrhythmia and heart failure treatment. Assessments of Ca 2+ leakage by quantification of spontaneous Ca 2+ leakage events (A) and the cells with SCR (B). The leaky phenotype was blocked by PKA inhibitor H89 treatment. SCR: spontaneous Ca 2+ release. The number in each column represents the number of cardiomyocytes analyzed. We used ten embryonic hearts for the WT group, ten embryonic hearts for the Rnd3 −/− group, and three embryonic hearts for the Rnd3 −/− +H89 group. WT: wild-type. Statistical significance was determined by an unpaired, two-tailed student's t test. Data are means s.d. (A) Immunoblotting analyses showed no obvious difference in β 1 AR protein levels between the WT and Rnd3-null hearts, while there was a significant increase in β 2 AR protein levels.
(B) The increase in β 2 AR protein levels in Rnd3 mutant hearts was verified and quantified by a radioligand binding assay. (C) q-PCR assessments of β 2 AR mRNA levels in the WT and Rnd3-null hearts. The same observations were detected in rat neonatal cardiomyocytes transfected with siRnd3 to knockdown Rnd3: panel (D) for the immunoblot analysis, panel (E) for the radioligand binding assay, and panel (F) for the q-PCR assay. At least 40 embryo hearts were pooled and used for the immunoblotting, radioligand binding and q-PCR assays. WT: wild-type. Ctrl: control. β 1 AR: β 1 -adrenergic receptor. β 2 AR: β 2 -adrenergic receptor. The number at the top of each immunoblot band in panel A and D represents the average of densitometries from three experiments, normalized by GAPDH. Statistical significance was determined by unpaired, two-tailed student's t test. Data are means ± s.d. 
